Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors
| Autor: | Elise Colle, Cindy Neuzillet, Pascal Hammel, Carole Vitellius, Anthony Turpin, Émeric Boisteau, Sandra Granier, Mathilde Wisniewski, Marc Hilmi, Christelle d’Engremont, Louis de Mestier |
|---|---|
| Přispěvatelé: | Hôpital Paul Brousse, Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), CHU Pontchaillou [Rennes], Service de pharmacologie médicale [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Service d'oncologie médicale (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Drug medicine.medical_specialty FOLFIRINOX media_common.quotation_subject medicine.medical_treatment [SDV]Life Sciences [q-bio] pancreatic cancer Review chemotherapy lcsh:RC254-282 olaparib maintenance PARP Olaparib nab-paclitaxel 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pancreatic cancer Internal medicine Metastatic pancreatic cancer medicine media_common Chemotherapy business.industry gemcitabine Neurotoxicity toxicity lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Gemcitabine 3. Good health 030104 developmental biology quality of life chemistry 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Therapeutic Advances in Medical Oncology Therapeutic Advances in Medical Oncology, SAGE Journals, 2020, 12, pp.175883592093794. ⟨10.1177/1758835920937949⟩ Therapeutic Advances in Medical Oncology, Vol 12 (2020) |
| ISSN: | 1758-8359 |
| DOI: | 10.1177/1758835920937949⟩ |
| Popis: | International audience; Metastatic pancreatic ductal adenocarcinomas (PDACs) are now more effectively controlled using chemotherapy combinations such as FOLFIRINOX and gemcitabine plus nab-paclitaxel (NabP) regimens with a subset of patients who achieve a sustained tumor stabilization or response. The next challenge is to design maintenance therapies that result in continued tumor control with minimal toxicity. Quality of life should always be a priority in these patients with prolonged survival. Gradually tapering off the intensity of chemotherapy by suppressing drug(s) in the combination is one option. Thus, maintenance with 5-fluorouracil or gemcitabine as single agents after FOLFIRINOX or gemcitabine-NabP induction, respectively, seems to be a promising approach to minimize neurotoxicity while maintaining efficacy. Another option is to introduce maintenance drug(s) with different anti-tumoral actions. The recent example of olaparib in patients with BRCA mutated PDAC provides a promising proof-of-concept of a switch maintenance strategy in this setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|